Litcius/Paper detail

Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK–mTOR Interplay

Huan Chen, Da T. Tran, Hsiu‐Chiung Yang, Sven Nylander, Yochai Birnbaum, Yumei Ye

2020Cardiovascular Drugs and Therapy94 citationsDOI

Topics & Concepts

MedicineDapagliflozinTicagrelorAMPKInflammasomeDiabetic cardiomyopathyInternal medicinePharmacologyEndocrinologymTORC1CardiomyopathyDiabetes mellitusInflammationType 2 diabetesMyocardial infarctionApoptosisHeart failurePI3K/AKT/mTOR pathwayProtein kinase AKinaseAcute coronary syndromeBiologyChemistryCell biologyBiochemistryCardiovascular Function and Risk FactorsDiabetes Treatment and ManagementAdenosine and Purinergic Signaling
Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK–mTOR Interplay | Litcius